Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Pressure on stock price.................
View:
Post by ggrellette on Mar 07, 2022 3:49pm

Pressure on stock price.................

is mounting quickly. The stock could collapse very quickly if news continues not to appear and it has to be excellent news or this stock will be back under 30 cents quicker then you can shake a stick.
Comment by fredgoodwinson on Mar 07, 2022 3:52pm
It was ever thus. It will all come down to the Clinic.
Comment by langosta on Mar 07, 2022 5:46pm
Looking back on this clowns last 20 or so posts regardless of stock, I think he should change his name to Mr Negativity.
Comment by enriquesuave on Mar 07, 2022 6:20pm
I don't expect always perfect results. If we hit 4 or more on 7, then we are on track to be the best single agent treatment by far.  6 or 7 on 7 and we are shaping up to be the best option period.  SP fluctuations don't mean much, we just need good data.  IMO. GLTA 
Comment by Lesalpes29 on Mar 07, 2022 6:41pm
Pressure not only here! But we hold even with dark red! almost everywhere.
Comment by CancerSlayer on Mar 08, 2022 3:54am
  I don't expect perfect results either, but based on the 70+% CR rate of "evaluable" patients to date who received at least one optimized treatment (11 in total), I selfishly expect at least "near-perfect" results for those patients who receive "two" optimized treatments.   Imo, that 70+% 90 day CR rate for that sample size is very likely not a ...more  
Comment by CancerSlayer on Mar 08, 2022 4:03am
  ...two NR patients
Comment by 99942Apophis on Mar 08, 2022 6:54am
Excellent argument for near perfect results CancerSlayer. I won't present a scenario for my expectations of a perfect case where all patients will now show CR however that is the results I foresee. The only death that occurred was in one patient because of other complications not related to Theralase's treatment. I don't think my expectations of perfect results to be unreasonable but ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250